Royalty financing in biotech and healthcare has exploded into a $5-6 billion annual market in North America, with transactions growing at a blistering 45% compound annual rate since 2018. Yet this booming alternative financing model remains almost entirely confined to US and Canadian borders. Europe has precisely one generalist

Background and Evolution Blackstone Life Sciences (BXLS) is the life-sciences investment arm of Blackstone, the world's largest alternative asset manager. The platform emerged in 2018 through Blackstone's strategic acquisition of Clarus Ventures – a seasoned life-sciences venture firm with a deep bench of MDs and

A delicate French dessert must rise perfectly under precise conditions. In biotechnology, Soufflé Therapeutics — a newly unveiled venture named after that airy confection — is attempting a similarly challenging feat. The Massachusetts-based startup has quietly assembled a recipe of cutting-edge RNA science and hefty financing to tackle one of

Introduction The Variable Capital Company (VCC) represents a transformative development in Singapore's fund management landscape, particularly for healthcare and life sciences investments. Introduced under the Variable Capital Companies Act 2018 and effective from January 14, 2020, the VCC provides a sophisticated corporate structure designed to enhance Singapore'

Introduction Special Purpose Vehicles (SPVs) play a pivotal role in the pharmaceutical and biotechnology sectors, facilitating innovative financing and structuring strategies. An SPV is a separate legal entity created for a specific purpose, with its own assets and liabilities, distinct from the sponsoring company [source]. By isolating assets or business

Bankruptcy remoteness is a crucial concept in structuring financial deals — especially royalty financing transactions in the biotechnology and pharmaceutical industry. In simple terms, bankruptcy remoteness means arranging a deal so that if one party (typically the biotech company or originator) goes bankrupt, the assets or cash flows involved in the

The week saw concentrated M&A activity focused on MASH and neurological assets totalling over $10 billion in deal value, alongside $665M in Series A venture rounds. No royalty financing deals announced during this specific week, though substantial partnership and manufacturing agreements supplemented major acquisitions. Acquisitions and M&

The Allure of the "Up To" Deal Every so often, a biotech startup announces a blockbuster partnership with a big pharmaceutical company, and champagne corks start popping. The press release trumpets a headline number: "Small Biotech X signs deal worth up to $500 million!" Founders daydream

Executive Summary CureDuchenne Ventures does not operate as a traditional venture capital firm. Instead, it represents a venture philanthropy model where a nonprofit organization makes equity investments in biotechnology companies using donor dollars, targeting a single rare disease: Duchenne muscular dystrophy. This organizational structure creates unique dynamics, incentives, and constraints

Introduction Rome Therapeutics is a Boston-based biotechnology company on a mission to drug the "dark genome" – the vast portion of human DNA once dismissed as "junk" but now known to harbor repetitive elements implicated in disease. Founded in 2020 by CEO Rosana Kapeller, M.D.